Daniel G. Fuster
@Dan_Fuster
Followers
77
Following
108
Media
3
Statuses
122
Associate Professor of Nephrology @inselgruppe and @unibern. Kidney stone and rare kidney disease enthusiast. Passion for skiing, climbing and alpinism.
Switzerland
Joined March 2023
IgA Nephropathy with two global leaders @MarkusAtHome: An honor and pleasure to host @IgAN_JBarratt @jradnephro For our best of @NDTsocial webinar picked by @AKronbichler @hjanders_hans
https://t.co/HRPnkcKnHe via @YouTube
0
5
10
@Tobias_B_Huber Thank you, dear Tobi — your friendship and leadership mean a great deal. No one advances alone; we are all part of a shared mission to understand and ultimately eliminate kidney disease. The future of nephrology is bright when science, collaboration, and vision come together.
0
3
14
Happy to see our review on "challenges" in ANCA-associated vasculitis published in @NatRevRheumatol! A special thanks to the Editorial Team and also @martacasalmoura for leading this initiative! #vasculitis @EUVAS19 @vasculitides
New content online: Challenges in the diagnosis, classification and prognosis of ANCA-associated vasculitis https://t.co/2hS0GnMCjc
0
39
102
Congratulations Biff. Well deserved
ASN Kidney News Oct/Nov 2025 Biff F. Palmer to Receive Robert G. Narins Award for Contributions in Education https://t.co/jsNXAZ1InN
@asnpublications
0
1
5
Congrats to @samirparikhmd and team for a breakthrough paper in @ScienceMagazine showing that somatically acquired heteroplasmic mtDNA mutations are a cause of chronic kidney disease and are functionally reversible. @ASNKidney @the_asci 👇👇
3
22
68
The inaugural YNA meeting came to an end! @sara___helena must be commended for the visibility of #YNA!
3
4
27
Congratulations to @milena_bond and the Firenze Team!
New article! Predictors of remission and relapse in retroperitoneal fibrosis. ➡️ Metabolic activity of RPF at 18F-FDG-PET is an important predictor of remission and relapse. 🔗 https://t.co/pE0tahUYvw
#IgG4 #PET #retroperitonealfibrosis #vasculitis #medtwitter @UNI_FIRENZE
1
1
11
An exceptional case we diagnosed 2 years ago with an extrarenal "crescent" formation (paravertebral mass). In the supplement you will see a selection of other rare manifestations including rupture of the A colica dextra. https://t.co/EZqYP4jXHQ
2
10
41
Just out in Nature Reviews Nephrology. Kidney stone disease: risk factors, pathophysiology and management. https://t.co/u8izdfaLjZ
0
3
6
Incredible work - congratulations Sarah and team ! JCI - Genetic variants predisposing to an increased risk of kidney stone disease
0
0
0
🎉Herzliche Gratulation! Daniel Fuster #inselgruppe hat mit Lia Bally, Beat Roth, Andreas Christe & Eva Segelov einen #IICT-Grant des @snf_ch erhalten für die EMPASTONE-Studie zur Prävention von #Nierensteinen mit Empagliflozin & Ernährungsberatung!👏 @MedFacultyUniBE
@unibern
0
1
9
Thank you Swiss National Science Foundation !! We just received 3.42 Mio CHF funding for our EMPASTONE trial. Looking forward to working with colleagues in Switzerland, Germany, France, Italy and the UK. https://t.co/lnnTDDpVlW
1
0
5
Dr Manuel Anderegg giving us the highlights of SWEETSTONE trial 🙌🏻 and the role of Empagliflozin in patients with calcium and acid uric stones. Remember, if you did not make it to a presentation, you can watch it on demand at ERA25 website. #era25 #beyondnephrology #ckd
1
6
17
✅Empagliflozin reduces urinary calcium and uric acid supersaturation in non-diabetic and non-CKD patients. The SWEETSTONE trial ⬇️ #ERA25 #beyondnephrology
EMPAGLIFLOZIN FOR URINARY SUPERSATURATION REDUCTION IN NON-DM PATIENTS WITH CALCIUM AND URIC ACID KIDNEY STONES (🪨SWEETSTONE🪨) - @Andereggman (DE)
0
28
77
Patients with rare kidney diseases account for 5–10% of people with CKD, but make up > 25% of those receiving kidney replacement therapy. Addressing unmet needs for these patients could positively impact long term KRT demand. Read the full article: https://t.co/mxeOlcXesu
0
12
16
Our new webinar in 🇩🇪🇦🇹🇨🇭🇱🇮 language: SGLT-2 Inhibitoren & Nierensteine: SWEETSTONE - Prof. D. Fuster, Prof. S. Trelle (Bern, Schweiz) WATCH NOW: https://t.co/OP4Zl5dQjH
@Dan_Fuster
@gunnar_heine
@MarcusSaemann
0
3
3
Just out in Nature Communications…..a mystery solved. It’s all about lipids in the regulation of intracellular NHEs. Thank you David for this great collaboration. https://t.co/h2zp2bbctL
0
0
2
Low BMD and fractures are common in kidney stone formers. HCTZ up to 50 mg daily did not preserve BMD compared to placebo over 3 years. Hydrochlorothiazide and Bone Mineral Density in Patients... : Clinical Journal of the American Society of Nephrology
journals.lww.com
and per-protocol analyses. Background Low bone mass and fractures are common among kidney stone formers, yet it remains unclear whether thiazides can help preserve bone mass. We aimed to evaluate the...
0
2
4
Incredible data set published in Cell. Look at Figure 6F ! #suPAR 👇👇 Atlas of the plasma proteome in health and disease in 53,026 adults: Cell
cell.com
A large-scale proteomics study involving 53,026 individuals maps 2,920 plasma proteins to 406 prevalent diseases, 660 incident diseases, and 986 health-related traits, identifying promising biomark...
0
8
39